

August 1, 2025

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra – Kurla Complex, Bandra (E),  
Mumbai – 400 051

Dear Sir,

**Sub: Clarification on news item appearing in <https://www.moneycontrol.com>**

This has reference to the email dated August 1, 2025 received from BSE Limited bearing reference number: L/SURV/ONL/RV/AJ/ (2025-2026)/ 55 and letter received from NSE bearing reference number: NSE/CM/Surveillance/15702, seeking clarification on the news that appeared on <https://www.moneycontrol.com> dated August 1, 2025 captioned ‘Trump Tariff News Live: GSK and AstraZeneca among top companies told to ‘cut US prices or else’.

In relation to the same, we would like to clarify that:

- (a) There were no negotiations taking place by the Company in relation to the news article mentioned on [www.moneycontrol.com](https://www.moneycontrol.com)
- (b) We are not aware of any information/announcement including pending announcement which in the Company’s opinion may have a bearing on the share price of the Company
- (c) There are no regulatory/legal proceedings initiated/ongoing in this regard.
- (d) The aforesaid news item does not pertain to AstraZeneca Pharma India Limited (‘Company’) which is currently listed on BSE Limited and National Stock Exchanges of India Limited. In absence of any other information in this regard, we are unable to comment on the materiality of the said news article, on the Company.

We thank you for drawing our attention and assure you of Company’s continued adherence to its obligation under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For AstraZeneca Pharma India Limited

Manasa. R  
Company Secretary